TS-2021

AXP000059.1 · Oncolytic virus

Platform
adenovirus
Originator
Beijing Neurosurgical Institute
Sponsor
Beijing Neurosurgical Institute

Names

NameTypeSource
TS-2021 ambiguouspreferred name, codecurator, ctgov

Virus

Role
Oncolytic
Family
Adenoviridae
Virus
human adenovirus (serotype not reported)
Replication
conditionally replicating
Route
intratumoral
Source
evidence

Approvals

No regulatory approval recorded.

Clinical trials (1)

TrialTitleStatusPhaseStartPrimary completionEnrolmentConditions
NCT06585527Clinical Study on the Safety and Efficacy of TS-2021 in the Treatment of Recurrent Malignant GliomaUnknownPhase 12024-08-292026-01-0130Glioblastoma Multiforme; Glioma, Malignant

Recent changes

No changes recorded in its trials yet.

Clinical papers

No confirmed clinical papers yet.

Other papers

Preclinical studies, reviews and other papers that name it.

PubMedTitleJournalYearLinked by
PMID 40474210CD70 CAR-T cells empowered by TS-2021 through ex vivo transduction show potent antitumor efficacy against glioblastoma.Journal of experimental & clinical cancer research : CR2025name in title: TS-2021
PMID 38149454TS-2021, a third-generation oncolytic adenovirus that carried Ki67 promoter, TGF-β2 5'UTR, and IL-15 against experimental glioblastoma.Journal of medical virology2024name in title: TS-2021
PMID 39552450Olaparib Enhances the Efficacy of Third-Generation Oncolytic Adenoviruses Against Glioblastoma by Modulating DNA Damage Response and p66shc-Induced Apoptosis.CNS neuroscience & therapeutics2024name in abstract: TS-2021

Notes

Phase 1 in recurrent malignant glioma, NCT06585527, started August 2024. The registration gives no construct description; nothing entered that could not be verified.

How to cite

TS-2021 (AXP000059.1). The Abstractinator program registry, release 2026-11-17+2c46e992acfc. https://abstractinator.me/registry/AXP000059.html

Something wrong or missing? Suggest a correction (a GitHub issue; please link your evidence). Entry created 2026-11-11, updated 2026-11-11.